CureDuchenne and Dyne Therapeutics: DYNE-251 Transforming the Treatment Paradigm for DMD

Join us for this pre-recorded presentation and Q&A discussing Dyne’s Phase 1/2 clinical trial, DELIVER, evaluating DYNE-251 for the treatment of individuals with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.

Recorded Thursday, April 6, 2023

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.